Latest Period
Q1 2026
Security Snapshot
Lantern Pharma Inc. - Common Stock, par value $0.0001 per share (LTRN) Institutional Ownership
CUSIP: 51654W101
13F Institutional Holders and Ownership History from Q2 2020 to Q1 2026
Institutions Reporting
33
Shares (Excl. Options)
2,096,647
Price
$1.37
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, par value $0.0001 per share
- Symbol
- LTRN on Nasdaq
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 2,096,647
- Total 13F value
- $2,872,429
- Portfolio coverage rank
- 0%
- Share change
- -168,227
- Value change
- -$333,005
- Number of holders
- 33
- Shares outstanding
- 12,752,344
- SEC-reported price per share
- $3.50
- Insider filing price
- $3.50
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- LTRN - Lantern Pharma Inc. - Common Stock, par value $0.0001 per share is tracked under CUSIP 51654W101.
- 33 institutions reported positions in Q1 2026.
- 2 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 33 to 33 between Q4 2025 and Q1 2026.
- SEC-reported value moved from $6,910,016 to $2,872,429.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 33 institutions filings for Q1 2026.
Security key
51654W101
Latest holder period
Q1 2026
13F holders
33
13D/G owners
2
CIK / CUSIP context first
Open Q1 2026 holders
LTRN full holder history
Lantern Pharma Inc. SEC filings
Lantern Pharma Inc. company facts
Lantern Pharma Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 51654W101:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
2
Security
LTRN
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Bios Equity Partners, LP | 4.5% | -42% | $1,125,471 | -$518,991 | 571,305 | -32% | BIOS ADVISORS GP, LLC | 15 May 2026 |
| SATTERFIELD THOMAS A JR | 5.1% | $1,727,100 | 570,000 | Thomas A. Satterfield, Jr. | 30 Mar 2026 |
As of 31 Mar 2026, 33 institutional investors reported holding 2,096,647 shares of Lantern Pharma Inc. - Common Stock, par value $0.0001 per share (LTRN). This represents 16% of the company’s total 12,752,344 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
16%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| BIOS Capital Management, LP | 6.8% | 864,435 | -14% | 2.2% | $1,184,276 |
| VANGUARD CAPITAL MANAGEMENT LLC | 2.6% | 332,079 | 0% | 0% | $454,948 |
| CM Management, LLC | 2% | 250,000 | +11% | 0.29% | $342,500 |
| RENAISSANCE TECHNOLOGIES LLC | 0.91% | 116,000 | +5.1% | 0% | $158,920 |
| GEODE CAPITAL MANAGEMENT, LLC | 0.88% | 111,646 | +15% | 0% | $152,984 |
| Westside Investment Management, Inc. | 0.39% | 50,050 | +39% | 0.01% | $68,571 |
| Voss Capital, LP | 0.39% | 50,000 | 0% | 0% | $68,500 |
| VANGUARD FIDUCIARY TRUST CO | 0.39% | 49,607 | 0% | 0% | $67,962 |
| BlackRock, Inc. | 0.35% | 45,267 | +2.3% | 0% | $62,016 |
| DIMENSIONAL FUND ADVISORS LP | 0.3% | 38,060 | -2.7% | 0% | $52,142 |
| NewEdge Advisors, LLC | 0.21% | 27,399 | -28% | 0% | $37,542 |
| HORIZON KINETICS ASSET MANAGEMENT LLC | 0.21% | 26,373 | -4.4% | 0% | $36,131 |
| DAVENPORT & Co LLC | 0.19% | 23,814 | 0% | 0% | $32,625 |
| STATE STREET CORP | 0.19% | 23,652 | 0% | 0% | $32,403 |
| Bank of New York Mellon Corp | 0.17% | 21,301 | -20% | 0% | $29,182 |
| NORTHERN TRUST CORP | 0.12% | 15,589 | 0% | 0% | $21,357 |
| Focus Partners Wealth | 0.12% | 15,432 | -3.4% | 0% | $21,142 |
| Cetera Investment Advisers | 0.1% | 12,228 | 0% | 0% | $16,752 |
| UBS Group AG | 0.08% | 10,077 | -5.2% | 0% | $13,805 |
| Tower Research Capital LLC (TRC) | 0.03% | 3,569 | +324% | 0% | $4,890 |
| Vanguard Global Advisers, LLC | 0.02% | 2,355 | 0% | 0% | $3,226 |
| SBI Securities Co., Ltd. | 0.02% | 2,144 | +0.05% | 0% | $2,937 |
| CURIO WEALTH, LLC | 0.02% | 2,000 | 0% | 0% | $2,740 |
| WELLS FARGO & COMPANY/MN | 0.01% | 1,475 | 0% | 0% | $2,021 |
| MORGAN STANLEY | 0% | 601 | 0% | 0% | $823 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
24
Latest
Q1 2026
Rows shown
1-24 of 24
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 2,096,647 | $2,872,429 | -$333,005 | $1.37 | 33 |
| 2025 Q4 | 2,280,306 | $6,910,016 | -$64,644 | $3.03 | 33 |
| 2025 Q3 | 2,284,349 | $9,928,721 | +$166,361 | $4.35 | 31 |
| 2025 Q2 | 2,241,170 | $7,081,768 | -$615,229 | $3.16 | 34 |
| 2025 Q1 | 2,423,714 | $8,580,099 | -$194,908 | $3.54 | 30 |
| 2024 Q4 | 2,499,825 | $7,996,845 | -$160,960 | $3.19 | 32 |
| 2024 Q3 | 1,335,871 | $4,902,351 | +$118,888 | $3.67 | 31 |
| 2024 Q2 | 1,286,016 | $6,005,302 | +$572,129 | $4.67 | 39 |
| 2024 Q1 | 1,108,429 | $9,753,422 | +$324,907 | $8.80 | 33 |
| 2023 Q4 | 1,155,318 | $4,944,504 | +$6,767 | $4.28 | 29 |
| 2023 Q3 | 1,153,745 | $3,934,035 | -$18,036 | $3.41 | 26 |
| 2023 Q2 | 1,152,036 | $6,497,253 | +$385,814 | $5.64 | 25 |
| 2023 Q1 | 1,083,678 | $5,233,851 | +$124,192 | $4.83 | 21 |
| 2022 Q4 | 893,594 | $5,395,811 | -$1,734,422 | $6.04 | 21 |
| 2022 Q3 | 1,436,757 | $6,840,000 | +$106,232 | $4.78 | 23 |
| 2022 Q2 | 1,417,902 | $8,060,000 | -$230,429 | $5.70 | 25 |
| 2022 Q1 | 1,452,881 | $10,384,000 | -$1,687,241 | $7.14 | 25 |
| 2021 Q4 | 1,658,393 | $13,121,000 | -$563,118 | $7.98 | 31 |
| 2021 Q3 | 1,400,629 | $15,656,000 | +$604,001 | $11.18 | 24 |
| 2021 Q2 | 1,346,716 | $19,660,000 | -$1,578,997 | $14.60 | 19 |
| 2021 Q1 | 1,403,470 | $25,458,000 | +$23,880,194 | $18.14 | 21 |
| 2020 Q4 | 82,988 | $1,597,009 | -$1,643,167 | $19.24 | 10 |
| 2020 Q3 | 160,127 | $3,017,000 | +$710,980 | $18.84 | 11 |
| 2020 Q2 | 122,153 | $1,551,000 | +$1,551,000 | $12.39 | 5 |